Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67,206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.
Naeem A, Utro F, Wang Q, Cha J, Vihinen M, Martindale S, Zhou Y, Ren Y, Tyekucheva S, Kim AS, Fernandes SM, Saksena G, Rhrissorrakrai K, Levovitz C, Danysh BP, Slowik K, Jacobs RA, Davids MS, Lederer JA, Zain R, Smith CIE, Leshchiner I, Parida L, Getz G, Brown JR. Naeem A, et al. Among authors: zhou y. Blood Adv. 2023 May 9;7(9):1929-1943. doi: 10.1182/bloodadvances.2022008447. Blood Adv. 2023. PMID: 36287227 Free PMC article.
The Prostate Stromal Transcriptome in Aggressive and Lethal Prostate Cancer.
Ma C, Zhou Y, Fanelli GN, Stopsack KH, Fiorentino M, Zadra G, Mucci LA, Loda M, Tyekucheva S, Penney KL. Ma C, et al. Among authors: zhou y. Mol Cancer Res. 2023 Mar 1;21(3):253-260. doi: 10.1158/1541-7786.MCR-22-0627. Mol Cancer Res. 2023. PMID: 36511902 Free PMC article.
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia.
Ryan CE, Brander DM, Barr PM, Tyekucheva S, Hackett LR, Collins MC, Fernandes SM, Ren Y, Zhou Y, McDonough MM, Walker HA, McEwan MR, Abramson JS, Jacobsen ED, LaCasce AS, Fisher DC, Brown JR, Davids MS. Ryan CE, et al. Among authors: zhou y. Leukemia. 2023 Apr;37(4):835-842. doi: 10.1038/s41375-023-01830-2. Epub 2023 Jan 30. Leukemia. 2023. PMID: 36717653 Clinical Trial.
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL.
Ahn IE, Brander DM, Ren Y, Zhou Y, Tyekucheva S, Walker HA, Black R, Montegaard J, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P, Ng SY, Crombie J, Fisher DC, LaCasce AS, Arnason J, Hochberg EP, Takvorian RW, Abramson JS, Brown JR, Davids MS. Ahn IE, et al. Among authors: zhou y. Blood Adv. 2024 Feb 27;8(4):832-841. doi: 10.1182/bloodadvances.2023011574. Blood Adv. 2024. PMID: 38163317 Free PMC article. Clinical Trial.
Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer.
Li Y, He Y, Butler W, Xu L, Chang Y, Lei K, Zhang H, Zhou Y, Gao AC, Zhang Q, Taylor DG, Cheng D, Farber-Katz S, Karam R, Landrith T, Li B, Wu S, Hsuan V, Yang Q, Hu H, Chen X, Flowers M, McCall SJ, Lee JK, Smith BA, Park JW, Goldstein AS, Witte ON, Wang Q, Rettig MB, Armstrong AJ, Cheng Q, Huang J. Li Y, et al. Among authors: zhou y. Sci Transl Med. 2019 Dec 4;11(521):eaax0428. doi: 10.1126/scitranslmed.aax0428. Sci Transl Med. 2019. PMID: 31801883 Free PMC article.
67,206 results
You have reached the last available page of results. Please see the User Guide for more information.